Loading organizations...
Loading organizations...
Scipio Bioscience has raised $8.0M across 2 funding rounds.
Scipio Bioscience has raised $8.0M in total across 2 funding rounds.
Scipio Bioscience has raised $8.0M in total across 2 funding rounds.
Scipio Bioscience's investors include High-Tech Gründerfonds, Seventure Partners.
Scipio Bioscience is a Paris-based biotechnology company that develops and sells innovative sample preparation kits and analysis software specifically designed for single-cell RNA sequencing applications. Their products serve researchers in clinical and basic research settings, particularly in transcriptomics, by simplifying and improving the preparation of samples for single-cell studies. This addresses a critical bottleneck in single-cell sequencing workflows, enabling more accurate and efficient data generation. The company has shown growth momentum as single-cell technologies become increasingly central to biological and medical research[1][2][4].
Founded in Paris, Scipio Bioscience emerged from the need to streamline and standardize sample preparation for single-cell sequencing, a complex and rapidly evolving field. While specific founders’ names and detailed early milestones are not publicly highlighted, the company’s development as a biotech startup reflects a focus on bridging laboratory innovation with practical, user-friendly solutions. Early traction likely came from the adoption of their bench-top kits and software by research labs seeking reliable, reproducible methods for single-cell transcriptomics[1][4].
Scipio Bioscience rides the wave of the expanding single-cell genomics market, which is transforming biological research and personalized medicine. The timing is critical as demand for high-resolution cellular data grows across oncology, immunology, and developmental biology. Market forces such as advances in sequencing technology, decreasing costs, and increasing computational power favor companies like Scipio that address upstream sample preparation challenges. Their solutions help democratize single-cell analysis, influencing the broader ecosystem by enabling more labs to participate in cutting-edge research[1][2][4].
Looking ahead, Scipio Bioscience is well-positioned to capitalize on the growing adoption of single-cell sequencing in both academic and clinical research. Trends such as multi-omics integration, spatial transcriptomics, and personalized medicine will likely shape their product development and market expansion. Their influence may grow as they continue to innovate in sample prep and data analysis, potentially expanding into new applications and partnerships. Maintaining ease of use and reliability will be key to sustaining momentum in a competitive biotech landscape[1][4].
Scipio Bioscience has raised $8.0M across 2 funding rounds. Most recently, it raised $7.0M Series A in February 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2020 | $7.0M Series A | High-Tech Gründerfonds, Seventure Partners | |
| Nov 1, 2017 | $1.0M Seed | High-Tech Gründerfonds, Seventure Partners |
